Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

MLA

Rosen, Lee S., et al. “Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion.” Cancer, vol. 100, no. 1, Jan. 2004, pp. 36–43. EBSCOhost, https://doi.org/10.1002/cncr.11892.

APA

Rosen, L. S., Gordon, D. H., Dugan, W., Jr, Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B.-L., & Coleman, R. E. (2004). Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer, 100(1), 36–43. https://doi.org/10.1002/cncr.11892

Chicago

Rosen, Lee S, David H Gordon, William Dugan Jr, Pierre Major, Peter D Eisenberg, Louise Provencher, Mary Kaminski, et al. 2004. “Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion.” Cancer 100 (1): 36–43. doi:10.1002/cncr.11892.